Radionuclide Or Intended Radionuclide In An Organic Compound Patents (Class 424/1.37)
  • Patent number: 11478493
    Abstract: A hetero-targeted, dual-responsive nanogel to deliver chemotherapeutic agents to a metastatic cancer is provided. The nanogel includes a first chemotherapeutic agent, a second chemotherapeutic agent, a first targeting ligand, and a second targeting ligand. A method of treating cancer in a mammal with the nanogel are also provided.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: October 25, 2022
    Assignee: University of South Carolina
    Inventors: Peisheng Xu, Binglin Sui
  • Patent number: 11351276
    Abstract: The present disclosure concerns radiopharmaceutical compositions of radioactive halogenated benzylguanidine (such as radioiodinated MIBG) or a pharmaceutically acceptable salt, hydrate, or solvate thereof. In a preferred embodiment, the composition has at least 97% of radiochemical purity for at least 4 days. Advantageously, the compositions of the present disclosure may be devoid of parabens, which are carcinogenic and yet are used in known radioactive MIBG compositions. The present disclosure also provides processes of preparing a radioactive halogenated benzylguanidine composition. The compositions of the present disclosure can be used in diagnosis and treatment of various diseases.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: June 7, 2022
    Assignee: Jubilant Draximage Inc.
    Inventors: Robert William Riddoch, Abmel Xiques Castillo
  • Patent number: 11348702
    Abstract: An isotope production system, emanation generator, and process are disclosed for production of high-purity radioisotopes. In one implementation example, high-purity Pb-212 and/or Bi-212 isotopes are produced suitable for therapeutic applications. In one embodiment the process includes transporting gaseous radon-220 from a radium-224 bearing generator which provides gas-phase separation of the Rn-220 from the Ra-224 in the generator. Subsequent decay of the captured Rn-220 accumulates high-purity Pb-212 and/or Bi-212 isotopes suitable for direct therapeutic applications. Other high-purity product isotopes may also be prepared.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: May 31, 2022
    Assignee: Battelle Memorial Institute
    Inventor: Matthew J. O'Hara
  • Patent number: 11291737
    Abstract: An aqueous synthesis methodology for the preparation of silica nanoparticles (SNPs), core-shell SNPs having, for example, a size of 2 to 15 nm and narrow size-dispersion with size control below 1 nm, i.e. at the level of a single atomic layer. Different types of dyes, including near infrared (NIR) emitters, can be covalently encapsulated within and brightness can be enhanced via addition of extra silica shells. The surface may be functionalized with polyethylene glycol (PEG) groups and, optionally, specific surface ligands. This aqueous synthesis methodology also enables synthesis of 2 to 15 nm sized fluorescent core and core-shell aluminosilicate nanoparticles (ASNPs) which may also be surface functionalized. Encapsulation efficiency and brightness of highly negatively charged NIR fluorophores is enhanced relative to the corresponding SNPs without aluminum.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 5, 2022
    Assignee: CORNELL UNIVERSITY
    Inventors: Ulrich B. Wiesner, Kai Ma, Carlie Mendoza
  • Patent number: 11167047
    Abstract: An imaging nanoparticle comprising a plant virus particle having an interior surface and an exterior surface, an imaging agent that is linked to the interior and/or exterior surface, and a layer of biocompatible mineral such as silica coated over the exterior surface, is described. The imaging nanoparticle can be used in method of generating an image of a tissue region of a subject, by administering to the subject a diagnostically effective amount of an imaging nanoparticle and generating an image of the tissue region of the subject to which the imaging nanoparticle has been distributed.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: November 9, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole F. Steinmetz, Michael Bruckman, Lauren Randolph
  • Patent number: 11097021
    Abstract: The invention relates to a particulate material having a diameter in the range of from 5 to 200 microns comprising polymeric matrix stably incorporated radionuclide, processes for its production and method of radiation therapy utilising the particulate material.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 24, 2021
    Assignee: Sirtex Medical Limited
    Inventor: Bruce Nathaniel Gray
  • Patent number: 11020497
    Abstract: A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles. A rod-shaped plant virus or spherical nanoparticles including an imaging agent can be used in a method of generating an image of a tissue region of a subject such as a tumor or atherosclerotic tissue by administering the virus particle to the subject and generating an image of the tissue region of the subject to which the virus particle has been distributed.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: June 1, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Nicole Steinmetz, Michael Bruckman
  • Patent number: 10940219
    Abstract: Microspheres made of solid glass are used in radiation therapy, wherein the radiotherapeutic radionuclide must be generated in the glass by neutron activation. Microspheres of this type have a high radioactive load, are relatively heavy and contain additional non-therapeutic radionuclides. Additionally, radioactive microspheres made of plastic are used, which can be loaded with radionuclides by chemical means. These microspheres have a lower loading capacity, no additional radionuclides, and are lighter. The therapeutic radionuclide in both cases is Y-90. Microspheres made of nanoporous glass contain the therapeutic radionuclide, have a high loading capacity, require no neutron activation, can be parallel charged with multiple therapeutic and with diagnostic radionuclides, and are very light. It is possible to produce them in a radiochemical laboratory. Microspheres of this type can also be used diagnostically in preparation for therapy.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 9, 2021
    Assignee: SphereRx, LLC
    Inventor: Eberhard Fritz
  • Patent number: 10806801
    Abstract: A pharmaceutical composition includes a plurality of metal nanoparticles and at least one therapeutic agent. Each of the metal nanoparticles includes a core and a stabilizing agent coated on a surface of the core. The at least one therapeutic agent is attached to the stabilizing agent of the metal nanoparticles. Each of the therapeutic agent is an amphiphilic compound and has at least one hydrophobic chain interacting with the stabilizing agent. The pharmaceutical composition may further include a polymer shell encapsulating the metal nanoparticles and the therapeutic agent for enabling controlled release of the therapeutic agent. The pharmaceutical compositions are bifunctional and may be used for diagnosing and treating cancer. Methods for using the pharmaceutical compositions in conjunction with radiation therapy to diagnose and treat cancer are also provided.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: October 20, 2020
    Assignees: NATIONAL CHENG KUNG UNIVERSITY, NATIONAL CHENG KUNG UNIVERSITY HOSPITAL
    Inventors: Wu-Chou Su, Hai-Wen Chen, Tsung-Lin Tsai, Dar-Bin Shieh, Chia-Chun Chen
  • Patent number: 10765747
    Abstract: Methods of reducing aggregation of an aggregating IL-1ra comprising incubating IL-1ra with at least one accessory molecule are provided. Kits comprising IL-1ra and at least one accessory molecule are also provided. Pharmaceutical compositions comprising IL-1ra and at least one accessory molecule are also provided.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: September 8, 2020
    Assignee: SWEDISH ORPHAN BIOVITRUM AB (PUBL)
    Inventors: Andrei Raibekas, Bruce Kerwin
  • Patent number: 10688202
    Abstract: The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a number of advantages as compared with previously available options for preparing and utilizing medical isotopes, including, for example, they utilize metal(loid) chalcogen nanoparticles that serve as universal binders (e.g., via covalent or non-covalent (e.g., chelate) bonds) for medical isotopes to provide medical isotope labeled metal(loid) chalcogen nanoparticles. Surprisingly, the same metal(loid) chalcogen nanoparticles may be used to bind (e.g., covalent or non-covalent e.g., chelation) bonding) a wide variety of different useful medical isotopes without the use of traditional chelating agents.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: June 23, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Matthew A. Wall, Travis Shaffer, Stefan Harmsen, Jan Grimm, Moritz F. Kircher
  • Patent number: 10352859
    Abstract: An object of the present invention is to provide a method of detecting a specific tissue or cell in a sample tissue section and accurately specifying both the position(s) and amount of a biological substance of interest that is expressed on the specific tissue or cell.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: July 16, 2019
    Assignee: KONICA MINOLTA, INC.
    Inventors: Fuminori Okada, Takuji Aimiya, Kohsuke Gonda, Noriaki Ohuchi, Mika Watanabe
  • Patent number: 10328024
    Abstract: The present application relates to an amphiphilic polymer and a method of preparing the same. Furthermore, the present application relates to a micelle including a drug encapsulated by the amphiphilic polymer and a composition including the same. The amphiphilic polymer according to the present application has excellent drug encapsulation properties as well as good dispersion properties in an aqueous solution.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: June 25, 2019
    Assignees: LG Chem, Ltd., LG Household & Health Care Ltd.
    Inventors: Jeong Ae Yoon, Su Jeong Kim, Sun Hwa Lee, Woo Sun Shim, Sung Soo Yoon, Chang Hwan Ju, Jung A Kim, Nae Gyu Kang
  • Patent number: 10269464
    Abstract: A method of assisting with authenticating a workpiece is provided. In another aspect, ions are generated, accelerated in an accelerator, an isotope is created, and then the isotope is implanted within a workpiece to assist with authenticating of the workpiece. A further aspect includes a workpiece substrate, a visual marker and an isotope internally located within the substrate adjacent the visual marker.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 23, 2019
    Assignee: Board of Trustees of Michigan State University
    Inventors: Wolfgang Bauer, Bradley Sherrill
  • Patent number: 10251819
    Abstract: The present application relates to an amphiphilic polymer and a method of preparing the same. Furthermore, the present application relates to a micelle including a drug encapsulated by the amphiphilic polymer and a composition including the same. The amphiphilic polymer according to the present application has excellent drug encapsulation properties as well as good dispersion properties in an aqueous solution.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: April 9, 2019
    Assignees: LG Chem, Ltd., LG Household & Health Care Ltd.
    Inventors: Jeong Ae Yoon, Su Jeong Kim, Sun Hwa Lee, Woo Sun Shim, Sung Soo Yoon, Chang Hwan Ju, Jung A Kim, Nae Gyu Kang
  • Patent number: 10172867
    Abstract: A novel nanoparticle drug composition and method of use thereof is presented herein. The nanoparticle drug composition is comprised of at least one nanoparticle carrier, formed from the conjugation of PLGA and PEG, which encapsulates a drug such as afobazole and its derivatives, in a pharmaceutically acceptable carrier. The nanoparticle drug composition may be used to treat various diseases of the central nervous system involving excessive neuronal activity and inflammation such as stroke, Alzheimer's disease and anxiety.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: January 8, 2019
    Assignee: University of South Florida
    Inventors: Javier Cuevas, Christopher Katnik, Vijaykumar B. Sutariya
  • Patent number: 10086095
    Abstract: A rod-shaped plant virus having an interior surface and an exterior surface, and at least one imaging agent that is linked to the interior and/or exterior surface is described. The rod-shaped viruses can be combined into larger spherical nanoparticles. A rod-shaped plant virus or spherical nanoparticles including an imaging agent can be used in a method of generating an image of a tissue region of a subject such as a tumor or atherosclerotic tissue by administering the virus particle to the subject and generating an image of the tissue region of the subject to which the virus particle has been distributed.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: October 2, 2018
    Assignee: Case Western Reserve University
    Inventors: Nicole Steinmetz, Michael Bruckman
  • Patent number: 10076531
    Abstract: The present invention relates to a dialysis solution having at least one osmotic agent, wherein the osmotic agent is starch propylphosphonate.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: September 18, 2018
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventors: Robert Berlich, Thomas Schweitzer, Lisa Finkler, Thomas Heinze, Robert Hampe
  • Patent number: 9833508
    Abstract: The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a glut-1 antibody and a curcumin molecule. In another embodiment, the present invention provides a method of treating colon and/or breast cancer by administering a therapeutically effective amount of composition comprising a targeted construct attached to an inhibitor of NF-kB.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 5, 2017
    Assignee: Immix Biopharma, Inc.
    Inventors: Sean Senn, Ilya Rachman
  • Patent number: 9758439
    Abstract: Reactive nanocomposites comprising a metal nanoparticle functionalized with one or more layers of self-assembled protein cages and methods of making the same. The reactive nanocomposites according to the present invention demonstrate improved reaction kinetics and enhanced exothermic behavior.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: September 12, 2017
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Joseph M. Slocik, Christopher A. Krouse, Rajesh R. Naik
  • Patent number: 9701935
    Abstract: A magnetic particle comprises a polysaccharide matrix and a plurality of magnetic crystals dispersed in the matrix. A method for making magnetic particles comprises combining a basic solution with a metal ion solution and allowing the metal ions to oxidize to form magnetic crystals, and combining the magnetic crystals with a polysaccharide solution to form the magnetic particles.
    Type: Grant
    Filed: April 16, 2009
    Date of Patent: July 11, 2017
    Assignee: StemCell Technologies Inc.
    Inventors: Steven M. Woodside, Graeme Milton, Jason Dowd
  • Patent number: 9616245
    Abstract: This Invention relates to a method for achieving Focused Resonance Nanopermeabilization (FORN), which can be utilized in a novel anticancer therapy, and other selective permeabilization therapy and a machine to carryout the said method, where the transient permeabilization of cells by Focused Resonance pulses induces a significant increase of anti-tumor drug concentration in tumor or other interested cells. This invention can be successfully applied to the treatment of tumors in humans and Animals by using antimitotic drugs, chemotherapy. The invention is also useful in transpermeabilization of drug molecules for non cancer applications like vaccine and delivery of genetic materials for therapeutic purposes. Focused Resonance Nanopermeabilization (FORN), would enable a practical solution to a whole body application in its natural environment, without implanting electrodes or external probes, FORN is completely non-invasive. This invention also relates to an apparatus for carrying out the above method.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: April 11, 2017
    Inventor: Rajah Vijay Kumar
  • Patent number: 9561286
    Abstract: A compound composed of a phospholipid and basic amino acid residues is provided as is a sterically stabilized phospholipid nanocarrier containing the compound and use of the same in passive and targeted delivery of negatively charged therapeutic agents encapsulated within the nanocarrier.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: February 7, 2017
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Hayat Onyuksel, Fatima A. Khaja
  • Patent number: 9539348
    Abstract: The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods of use of such antibodies and the isolated antigen bound by such antibodies are also described.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: January 10, 2017
    Assignee: East Carolina University
    Inventors: Anne Elizabeth Kellogg, Diane A. Semer
  • Patent number: 9428401
    Abstract: A method for the separation of the rare-earth fission product poisons comprising providing a spent nuclear fuel. The spent nuclear fuel comprises UO2 and rare-earth oxides, preferably Sm, Gd, Nd, Eu oxides, with other elements depending on the fuel composition. Preferably, the provided nuclear fuel is a powder, preferably formed by crushing the nuclear fuel or using one or more oxidation-reduction cycles. A compound comprising Th or Zr, preferably metal, is provided. The provided nuclear fuel is mixed with the Th or Zr, thereby creating a mixture. The mixture is then heated to a temperature sufficient to reduce the UO2 in the nuclear fuel, preferably to at least to 850° C. for Th and up to 600° C. for Zr. Rare-earth metals are then extracted to form the heated mixture thereby producing a treated nuclear fuel. The treated nuclear fuel comprises the provided nuclear fuel having a significant reduction in rare-earths.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: August 30, 2016
    Assignee: U.S. Department of Energy
    Inventors: Jerry D. Christian, James W. Sterbentz
  • Patent number: 9421172
    Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: August 23, 2016
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Rimona Margalit, Dan Peer
  • Patent number: 9402903
    Abstract: Disclosed are a magnetic field-controlled movable bio-scaffold and a method for constructing the same. The bio-scaffold is highly biocompatible and can readily move to a target site under the control of an external magnetic field.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: August 2, 2016
    Assignee: DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hong Soo Choi, Sang Won Kim
  • Patent number: 9389226
    Abstract: There is disclosed a method for partially derivatizing a curved surface of particles in an electrically conducting solvent, said method comprises the steps: a) bringing particles in close contact with at least one surface by using a force, b) inducing a chemical reaction on at least one part of a particle by applying an electrical potential between said at least one surface and the electrically conducting solvent, and c) further reacting said at least one part of a particle where a chemical reaction has been induced in step b) above. There is further disclosed a partially derivatized particle as well as uses of the particle. Advantages include that the method is simple and only requires a potentiostat in addition to standard laboratory equipment, is inexpensive, time-efficient, and inherently parallel.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: July 12, 2016
    Assignee: LAB-ON-A-BEAD AB
    Inventors: Sven Oscarsson, Leif Nyholm, Peter Svedlindh, Klas Gunnarsson
  • Patent number: 9346855
    Abstract: Described herein are modifications and adaptations of iron storage proteins for a novel photo-initiated approach to cancer therapy whereby cells are killed via production of iron-generated hydroxyl radicals. The iron is photo-released from a protein scaffold that includes tumor-targeting peptides and/or proteins fused to the exterior surface of the protein scaffold. One or more photosensitizers are coupled to the protein shell. The multiple tumor-targeting peptides and/or proteins will bind to specific hyperexpressed receptors on the cancer cells. After binding of the photosensitizer-iron-loaded protein to the cancer cells, photochemical excitation of the photosensitizers with tissue-penetrating near-infrared light triggers release of “free” ferrous iron, which in oxic or mildly hypoxic intracellular environments generates toxic hydroxyl radicals via Fenton chemistry. This light-triggered release of “free” iron overwhelms the cancer cells' defenses against free radicals.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: May 24, 2016
    Assignee: Board of Regents of the University of Texas System
    Inventor: Donald M. Kurtz, Jr.
  • Patent number: 9174187
    Abstract: Provided herein are methods for making water-soluble nanoparticles comprising a core/shell nanocrystal that is coated with a surface layer comprising enough hydrophilic ligands to render the nanoparticle water soluble or water dispersable. Methods for crosslinking molecules on the surface of a nanoparticle, which methods can be used on the above water-soluble nanoparticles also are provided. Nanoparticle compositions resulting from these methods are also provided.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: November 3, 2015
    Assignee: Life Technologies Corporation
    Inventors: Eric Tulsky, Kari Haley, Imad Naasani, John Mauro, Roman Rozhkov, Joseph A. Treadway
  • Patent number: 9061079
    Abstract: Methods of targeting atherosclerotic plaques using LyP-1 related peptides are provided. In some embodiments, the methods include administering a peptide comprising a LyP peptide to an animal, wherein the peptide homes to an atherosclerotic plaque, thereby targeting the atherosclerotic plaque. Also provided are methods for ameliorating a sign or symptom associated with an inflammatory condition using LyP-1 related peptides.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: June 23, 2015
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Juliana Hamzah
  • Patent number: 8961949
    Abstract: The present invention provides a polymer-metal complex composite, which comprises a block copolymer capable of serving as a constituent member of a polymeric micelle and a metal complex having MRI contrast ability, accumulates in a tumor-specific manner, achieves high image contrast even in a small amount, and has reduced side effects and a long retention time in blood. The polymer-metal complex composite of the present invention comprises a block copolymer (A) represented by general formula (a) and a metal complex (B) having MRI contrast ability, wherein the composite comprises a structure in which a carboxyl anion of poly(carbo) in the copolymer (A) is attached to the metal complex (B) via a metal atom (M).
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: February 24, 2015
    Assignee: Japan Science and Technology Agency
    Inventors: Kazunori Kataoka, Sachiko Kaida, Horacio Cabral, Michiaki Kumagai, Masaki Sekino
  • Patent number: 8945510
    Abstract: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: February 3, 2015
    Assignee: Probiodrug AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Hans-Ulrich Demuth
  • Publication number: 20150023869
    Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 22, 2015
    Applicant: ISOTHERAPEUTICS GROUP LLC
    Inventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
  • Publication number: 20150004096
    Abstract: The invention relates to cancer receptor-specific bioprobes for single photon emission computed tomography (SPECT) and computed tomography (CT) or magnetic resonance imaging (MRI) for dual modality molecular imaging. The base of the bioprobes is the self-assembled polyelectrolytes, which transport gold nanoparticles as CT contrast agents, or SPION or Gd(III) ions as MR active ligands, and are labeled using complexing agent with technetium-99m as SPECT radiopharmacon. Furthermore these dual modality SPECT/CT and SPECT/MR contrast agents are labeled with targeting moieties to realize the tumorspecificity.
    Type: Application
    Filed: December 19, 2013
    Publication date: January 1, 2015
    Applicant: BBS Nanotechnology Ltd.
    Inventors: János BORBÉLY, István HAJDU, Magdolna BODNÁR, Zsuzsanna CSIKÓS
  • Publication number: 20140363371
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Application
    Filed: December 19, 2012
    Publication date: December 11, 2014
    Inventors: Juntao Luo, Kit Lam
  • Publication number: 20140314664
    Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.
    Type: Application
    Filed: January 6, 2012
    Publication date: October 23, 2014
    Applicant: ANP Technologies, Inc.
    Inventors: Dujie Qin, Ray Yin, Jing Pan, Yubei Zhang
  • Patent number: 8852550
    Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: October 7, 2014
    Assignee: GE Healthcare Limited
    Inventors: Colin Mill Archer, Harry John Wadsworth, Torgrim Engell
  • Publication number: 20140271461
    Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix
  • Publication number: 20140234210
    Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.
    Type: Application
    Filed: July 9, 2012
    Publication date: August 21, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie A. Kramer, Christopher Y. Poon
  • Patent number: 8808664
    Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: August 19, 2014
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20140227177
    Abstract: The invention provides a scanning suspension comprising a particle which is capable of at least in part disturbing a magnetic field, wherein said particle comprises a diameter of at least 1 ?m, and use thereof for obtaining a scanning image. Preferably, said particle comprises holmium and a composition capable of essentially maintaining its structure during irradiation. A particle of the invention is suitable for preparing a kit of parts, comprising a diagnostic and a therapeutic composition which both comprise particles of the invention with essentially the same chemical structure, wherein said therapeutic composition is more radioactive than said diagnostic composition. Said kit of parts is especially suitable for treatment of a tumor. First, the distribution of a particle of the invention within an individual can be determined with a scanning image obtained with said scanning composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: August 14, 2014
    Applicants: Universiteit Utrecht Holding B.V., Universitair Medisch Centrum Utrecht
    Inventors: Johannes Franciscus Wilhelmus NIJSEN, Alfred Dirk VAN HET SCHIP, Bernard Antoni ZONNENBERG
  • Publication number: 20140199235
    Abstract: The present invention relates to a nanoparticle having a linker connected to a long alkane or alkene chain, and a method for preparing the nanoparticle. The alkyl chain of C10-30 introduced with a ligand of the present invention can be coated on a hydrophobic nanoparticle through a noncovalent bond, enabling easy introduction of various ligands to the nanoparticle, and the nanoparticle having various functional groups prepared using the method can be applied to fluorescent detection, MRI, raman spectroscopy, optical detection, PET, SPECT, or gamma image device, and the ligand of the visualization agents can be modified to be used for new vessels detection, cancer cell detection, immunocyte detection, hepatocyte detection, cell death detection, and gene detection.
    Type: Application
    Filed: January 31, 2012
    Publication date: July 17, 2014
    Applicant: SNU R&DB FOUNDATION
    Inventors: Jae Min Jeong, Young Kyoung Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee
  • Patent number: 8691280
    Abstract: The invention provides a microsphere comprising an organic lanthanide metal complex wherein the lanthanide metal is present in an amount of more than 20 wt %, based on total microsphere. The invention further provides a suspension comprising such a microsphere. In addition, the invention relates to a method for preparing said microsphere, and the use of the microsphere(s) or suspension for treating a malignancy and/or obtaining a scanning image.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: April 8, 2014
    Assignees: UMC Utrecht Holding B.V., Stichting voor de Technische Wetenschappen
    Inventors: Johannes F. W. Nijsen, Wouter Bult, Alfred D. van het Schip
  • Patent number: 8668898
    Abstract: Methods and compositions for effectively lowering the carbon-14 content, particularly of DNA and histones in vertebrates, especially humans, to significantly below normal background levels and thereby reduce chromosomal damage using nutritional or dietary supplements based on low radiocarbon DNA, amino acid and histone precursors, further preferably including those which contribute the largest share of histone carbon atoms. Administration of the supplements during the earliest and/or most active growth stages of life is particularly beneficial. Particularly useful supplements are prepared by combining low radiocarbon precursor compounds with ordinary supplement or dietary components that exhibit substantially normal background radiocarbon concentrations.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: March 11, 2014
    Assignee: Radiocarb Genetics, Inc.
    Inventor: Christopher P. Williams
  • Patent number: 8633337
    Abstract: The present invention provides a method for the preparation of a radiolabeled guanidine derivative, in particular wherein the radiolabeled guanidine derivative is a positron emission tomography (PET) tracer. Certain intermediates useful in said method are also provided, as well as means for carrying out said method in an automated fashion. The method of the invention provides advantages over known methods for the preparation of radiolabeled guanidine derivatives.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: January 21, 2014
    Assignee: GE Healthcare Limited
    Inventors: Anders Brathe, Andreas Olsson, Mikkel Thaning, Steffen Bugge
  • Publication number: 20140017165
    Abstract: This invention relates generally to the discovery of novel nanoparticles for delivery of DNA double-stranded break (DSB) repair enzyme inhibitors such as wortmannin or wortmannin analogues. In one embodiment, these nanoparticles comprise a polylactide polyglycolide (PLGA) copolymer and a polyethylene glycol (PEG). In addition methods of treatment and methods of enhancing radiation treatments are also provided.
    Type: Application
    Filed: January 11, 2012
    Publication date: January 16, 2014
    Inventors: Zhuang Wang, Michael Edward Pacold, Michael Edward Werner, Shrirang Karve
  • Patent number: 8623322
    Abstract: The present invention is directed to novel non-invasive diagnostic tools to diagnose numerous infectious disease states or conditions. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these disease states. The novel imaging probe is capable of detecting infected cells, as well tissue. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to therapeutic treatments and other interventions or therapies used in the treatment of these disease states or conditions. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states. Pharmaceutical compositions are also described.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: January 7, 2014
    Assignee: STC.UNM
    Inventor: Jeffrey P. Norenberg
  • Patent number: 8613904
    Abstract: The present disclosure concerns methods of administering and detecting a distinguishable agent in a sample from and assessing the condition of an organ in a subject. In a particular embodiment, the present invention concerns methods of detecting and comparing the cholate shunt, in a subject, preferably in a subject with chronic hepatitis C. In certain embodiments, the methods may comprise obtaining a sample from a subject such as a blood or saliva sample after administering an oral and intravenous dose of a distinguishable agent such as cholate and analyzing the sample clearance of the distinguishable agent from the subject and comparing the clearance levels in order to assess hepatic health. In another embodiment, the methods may comprise analyzing a sample from a subject for the presence of a distinguishable agent such as cholate and applying information obtained from analyzing the presence of the distinguishable agent to determine a treatment for a medical condition of the subject.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: December 24, 2013
    Assignee: The Regents of the University of Colorado
    Inventors: Gregory Thomas Everson, Michael Anthony Martucci
  • Publication number: 20130302243
    Abstract: Disclosed are novel, targeted, self-assembled nanoparticles radiolabeled with technetium-99m (Tc-99m) as radiodiagnostic compositions, methods of using these compositions and methods for preparing such radiolabeled compositions. Specifically, the compositions of the nanoparticles are composed of self-assembled polyelectrolyte biopolymers having targeting moieties, which can be suitable for targeted delivery of radionuclide metal ions complexed to the nanoparticles. These radiolabeled nanoparticles can specifically bind and internalize into the targeted tumor cells to realize the receptor mediated uptake. Radiolabeled, targeted nanoparticulate composition, methods for making, radiolabeling and using such compositions in the field of diagnosis and therapy are also provided.
    Type: Application
    Filed: May 7, 2013
    Publication date: November 14, 2013
    Applicant: BBS NanoMedicina Zrt.
    Inventors: János Borbély, Magdolna Bodnár, Lajos Balogh, András Polyák